Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The NIHR Research and Innovation for Global Health Transformation (RIGHT) programme has awarded £4.9 million to help fund a project investigating epilepsy in sub-Saharan Africa.

Research participant in EEG cap wired up to computer carrying out a computer-based task
EEG being used with child with epilepsy in Kenya

The National Institute for Health Research (NIHR) has invested £34 million of funding into global health research projects to tackle epilepsy, infection-related cancers and severe stigmatising skin diseases in low- and middle-income countries. 

The NIHR Research and Innovation for Global Health Transformation (RIGHT) programme has awarded funding to eight projects, including the Epilepsy Pathway Innovation in Africa (EpInA) project led by researchers from the University of Oxford.

Arjune Sen (Nuffield Department of Clinical Neurosciences) and Charles Newton (Department of Psychiatry) together with colleagues at University College London and Newcastle University will work with colleagues in Ghana, Kenya and Tanzania. They will conduct a series of studies designed to help experts better understand the history of epilepsy, investigate why people with epilepsy are so disadvantaged, and then set out to improve the situation.

 

We are truly delighted to have been awarded the NIHR RIGHT grant and to start on the EPInA project! It is a privilege to be able to perform this work which we hope will make meaningful and sustained improvements in the care of people with epilepsy in Africa.
- Associate Professor Arjune Sen

The project will include:

  • Preventing epilepsy in southern Tanzania
  • Developing an app to help healthcare workers diagnose epilepsy, allowing earlier treatment
  • Determining if text messaging can increase the number of people who take their medication correctly
  • Training primary health care staff in the care of people with epilepsy
  • Developing students and other people to lead future projects in epilepsy.

 

 

 

Similar stories

Attention and memory deficits persist for months after recovery from mild COVID

Researchers from Oxford’s Nuffield Department of Clinical Neurosciences and Department of Experimental Psychology have shown that people who have had COVID but don’t complain of long COVID symptoms in daily life nevertheless can show degraded attention and memory for up to six to nine months.

New spinout company: Human-Centric Drug Discovery

Human-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.

Funding received for research into Motor Neuron Disease

A £210,000 donation from the Alan Davidson Foundation has been made to our Department to advance our world-leading research into Motor Neuron Disease. The funding will support a project manager to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis.

Protein test could lead to earlier and better diagnosis of Parkinson’s

Scientists have observed the clumping of alpha-synuclein in the cerebrospinal fluid taken from people with Parkinson's. The findings offer hope that a pioneering new clinical test could be developed to diagnose Parkinson's correctly in its early stages.

Evaluating risk to people with epilepsy during the COVID-19 pandemic - study wins international prize

In May 2020 our researchers initiated a global project to investigate how COVID-19 has affected people with epilepsy, their carers and health care workers.